MOLECULAR GENETIC ASPECTS OF HEPATOCELLULAR CARCINOMA PATHOGENESIS AND CURRENT OPTIONS OF DRUG THERAPY

MOLECULAR GENETIC ASPECTS OF HEPATOCELLULAR CARCINOMA PATHOGENESIS AND CURRENT OPTIONS OF DRUG THERAPY

Liver cancer is widespread neoplasm type that ranks second among the causes of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) is the main form of liver cancer generally detected at advanced stages in most patients. HCC development is a result of accumulation of various somatic mo...

Full description

Bibliographic Details
Main Author: A. S. Makarova
Format: Article
Language:Russian
Published: ABV-press 2017-12-01
Series:Uspehi Molekulârnoj Onkologii
Subjects:
hepatocarcinoma
next-generation sequencing
gsea
snea
targeted therapy
immunotherapy
Online Access:https://umo.abvpress.ru/jour/article/view/113
id doaj-5dcd50532c9949859d7182f39674ab17
record_format Article
spelling doaj-5dcd50532c9949859d7182f39674ab172021-07-29T08:12:33ZrusABV-pressUspehi Molekulârnoj Onkologii2313-805X2413-37872017-12-014481610.17650/2313-805X-2017-4-4-8-16106MOLECULAR GENETIC ASPECTS OF HEPATOCELLULAR CARCINOMA PATHOGENESIS AND CURRENT OPTIONS OF DRUG THERAPYA. S. Makarova0Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaLiver cancer is widespread neoplasm type that ranks second among the causes of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) is the main form of liver cancer generally detected at advanced stages in most patients. HCC development is a result of accumulation of various somatic molecular alterations. Different HCC etiology and chronic liver diseases cause numerous and heterogeneous genetic and epigenetic aberrations that determine diverse gene expression alterations in HCC. Molecular heterogeneity limits the efficacy of targeted therapy that is currently the essential approach for advanced stage HCC treatment.The present review considers the main genetic and epigenetic alterations detected in HCC, results of transcriptomic investigations and systems biology analysis of the data. Up-to-date information on application of targeted drugs and immune checkpoint inhibitors in HCC therapy are discussed.https://umo.abvpress.ru/jour/article/view/113hepatocarcinomanext-generation sequencinggseasneatargeted therapyimmunotherapy
collection DOAJ
language Russian
format Article
sources DOAJ
author A. S. Makarova
spellingShingle A. S. Makarova
MOLECULAR GENETIC ASPECTS OF HEPATOCELLULAR CARCINOMA PATHOGENESIS AND CURRENT OPTIONS OF DRUG THERAPY
Uspehi Molekulârnoj Onkologii
hepatocarcinoma
next-generation sequencing
gsea
snea
targeted therapy
immunotherapy
author_facet A. S. Makarova
author_sort A. S. Makarova
title MOLECULAR GENETIC ASPECTS OF HEPATOCELLULAR CARCINOMA PATHOGENESIS AND CURRENT OPTIONS OF DRUG THERAPY
title_short MOLECULAR GENETIC ASPECTS OF HEPATOCELLULAR CARCINOMA PATHOGENESIS AND CURRENT OPTIONS OF DRUG THERAPY
title_full MOLECULAR GENETIC ASPECTS OF HEPATOCELLULAR CARCINOMA PATHOGENESIS AND CURRENT OPTIONS OF DRUG THERAPY
title_fullStr MOLECULAR GENETIC ASPECTS OF HEPATOCELLULAR CARCINOMA PATHOGENESIS AND CURRENT OPTIONS OF DRUG THERAPY
title_full_unstemmed MOLECULAR GENETIC ASPECTS OF HEPATOCELLULAR CARCINOMA PATHOGENESIS AND CURRENT OPTIONS OF DRUG THERAPY
title_sort molecular genetic aspects of hepatocellular carcinoma pathogenesis and current options of drug therapy
publisher ABV-press
series Uspehi Molekulârnoj Onkologii
issn 2313-805X
2413-3787
publishDate 2017-12-01
description Liver cancer is widespread neoplasm type that ranks second among the causes of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) is the main form of liver cancer generally detected at advanced stages in most patients. HCC development is a result of accumulation of various somatic molecular alterations. Different HCC etiology and chronic liver diseases cause numerous and heterogeneous genetic and epigenetic aberrations that determine diverse gene expression alterations in HCC. Molecular heterogeneity limits the efficacy of targeted therapy that is currently the essential approach for advanced stage HCC treatment.The present review considers the main genetic and epigenetic alterations detected in HCC, results of transcriptomic investigations and systems biology analysis of the data. Up-to-date information on application of targeted drugs and immune checkpoint inhibitors in HCC therapy are discussed.
topic hepatocarcinoma
next-generation sequencing
gsea
snea
targeted therapy
immunotherapy
url https://umo.abvpress.ru/jour/article/view/113
work_keys_str_mv AT asmakarova moleculargeneticaspectsofhepatocellularcarcinomapathogenesisandcurrentoptionsofdrugtherapy
_version_ 1721257121975107584

Similar Items